CRISPR Therapeutics (NASDAQ:CRSP) Bolsa

CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Russia,Moscow,24.06.2021,Logo,Of,Financial,Investing,Fund,Ark,Invest

Equities

News

Markets

ETFs

ARKK

ARKW

ARKX

CRSP

KTOS

PACB

PLTR

SHOP

Ark Invest modificó su cartera vendiendo acciones de Palantir y comprando AMD y Shopify. ¿Qué estrategia hay detrás?

Ark Invest refuerza su apuesta por AMD mientras reduce exposición a Palantir

CRISPR Therapeutics AG

McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) has outperformed the market over the past 20 years by 4.27% on an annualized basis producing an average annual return of 12.58%. Currently, McDonald's has a market capitalization of $222.90 billion. 
Buying $100 In MCD: If an investor had bought $100 of MCD stock 20 years ago, it would be worth $1,055.10 today based on a price of $311.99 for MCD at the time of writing.
<h3>McDonald's's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749075313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Hockey is the top sport in Canada, and the<a href="https://www.benzinga.com/topic/nhl" target="_blank" rel="noopener"> National Hockey League</a> reigns supreme among professional sports leagues. Seven Canadian teams compete in the league for the coveted Stanley Cup trophy.
After a 30+ year drought of no Stanley Cups, Canada is four wins away from seeing a championship return to the country.
What Happened: Canada beat the United States in the 4 Nations Face-Off challenge in February, winning the championship game, which gained increased significance with U.S. President Donald Trump calling for Canada to <a href="https://www.benzinga.com/news/global/24/12/42300450/trump-told-trudeau-canada-could-avoid-tariffs-by-becoming-51st-state-a-look-at-sectors-trade-war-could-impact">become the 51st state.</a>
After Canada's win, then-Canadian Prime Minister Justin Trudeau poked fun at Trump.
"You can't take our country – and you can't take our game," Trudeau <a href="https://www.nytimes.com/2025/02/21/world/canada/trudeau-trump-hockey-canada-us-feud.html">tweeted</a>.
While Trudeau may have been correct about the international tournament, he wasn't entirely truthful about Canada's "game."
Hockey may be the most loved sport in Canada, but the last time a team from the country won the Stanley Cup was in 1993, when the Montreal Canadiens won the championship.
In last year's NHL Playoffs, around 75% of the current NHL players were not born the last time a Canadian team won a Stanley Cup, according to&nbsp;<a href="https://www.espn.com/nhl/insider/story/_/id/39815401/canada-stanley-cup-playoffs-drought-end-vancouver-edmonton-winnipeg-toronto" target="_blank" rel="noreferrer noopener">ESPN</a>. About 3% of NHL players today were five years old or older and likely able to remember a Canadian team winning the cup.
Since the Canadiens won the Stanley Cup in 1993, there have been 15 U.S teams to win the championship.
History shows that Canadian teams still rank among the all-time best in NHL and Stanley Cup history. The Canadiens rank first with 23 Stanley Cup wins. Ranking second is also a Canadian team, with the Maple Leafs winning 13 Stanley Cups. The Edmonton Oilers rank sixth all-time with five Stanley Cup wins.
Canada had five of their seven NHL teams make the 2024-2025 NHL Playoffs, and one remains with a chance to end the drought.
Read Also: <a href="https://www.benzinga.com/general/education/25/04/45072237/5-things-you-might-not-know-about-canadian-prime-minister-mark-carney-from-playing-college-hockey-to-bitcoin">5 Things You Might Not Know About Canadian Prime Minister Mark Carney: From Playing College Hockey To Bitcoin</a>
2025 Stanley Cup Matchup: For the second straight season, the Oilers and Florida Panthers meet in the Stanley Cup Finals. Last season saw the Panthers win their first championship in franchise history beating the Oilers in seven games of the best-of-seven series.
NHL history has witnessed several back-to-back Stanley Cup final matchups, and in many cases, the team that lost the first year ends up winning a championship the following season in the rematch.
The best-of-seven series kicks off Wednesday, June 4, with television coverage of the entire series belonging to Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>). Games all start at 8 p.m. ET and will be available to watch on TNT, truTV and to stream on Max.
Here is the schedule:
<ul class="wp-block-list">
<li>Wednesday, June 4 in Edmonton</li>
<li>Friday, June 6 in Edmonton</li>
<li>Monday, June 9 in Florida</li>
<li>Thursday, June 12 in Florida</li>
<li>Saturday, June 14 in Edmonton (if necessary)</li>
<li>Tuesday, June 17 in Florida (if necessary)</li>
<li>Friday, June 20 in Edmonton (if necessary)</li>
</ul>
Television viewership for Warner Bros. Discovery's coverage of the games has <a href="https://awfulannouncing.com/nhl/stanley-cup-playoffs-sharp-us-ratings-decline-through-conference-finals.html">averaged </a>947,000 through the conference finals, down 20% year-over-year. NHL Playoffs coverage by Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) unit ESPN has averaged 966,000 viewers, down 31% year-over-year.
Having many Canadian teams in the playoffs may be hurting U.S. viewership, but it could also benefit Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>), which has rights in Canada. NHL Playoffs viewership is averaging 1.97 million viewers in Canada, up 21% year over year.
Stanley Cup Betting Odds: The betting markets favor the Oilers in the series slightly with sportsbook DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) listing odds at -120 for the Oilers and +100 for the Panthers.
On the prediction market, <a href="https://kalshi.com/markets/kxnhl/stanley-cup" target="_blank" rel="noopener">Kalshi, </a>the odds are 55% for the Oilers and 45% for the Panthers.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXNHL-25?color_scheme=light&#038;widget_size=medium&#038;variant=a&#038;ids=KXNHL-25-EDM&#038;ids=KXNHL-25-FLA&#038;ids=KXNHL-25-NYI" width="488px" height="196px" style="border:0"></iframe>
Users can bet on individual games and the series&#8217; exact results. Kalshi users predict the series will go six or seven games, with Edmonton winning 4-2 and Florida winning 4-3 ranking second at 20% and Edmonton winning 4-3 the top pick at 21% of wagers.
On prediction market <a href="https://polymarket.com/event/stanley-cup-winner?tid=1749071639278">Polymarket</a>, the Oilers are listed as the favorite at 53% with the Panthers given odds of 48% to win the Stanley Cup.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44633812/trump-tariffs-could-hurt-national-hockey-league-commissioner-has-concerns-hopes-things-can-get-back-to-a-normal-reality">Trump&#8217;s Tariff Push Raises NHL Concerns: League Hopes For Return To &#8216;Normal Reality&#8217;</a></li>
</ul>
Photo: Keith J Finks / Shutterstock.com

Sports Betting

Sports

DKNG

Canada's 32-Year Stanley Cup Drought Could End In 2025: Oilers Vs. Panthers, Odds, Schedule, How To Watch

Canaccord Genuity Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CF#TSX">CF</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.17 by 29.41 percent. This is a 20 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $461.23 million which missed the analyst consensus estimate of $466.95 million by 1.23 percent. This is a 12.76 percent increase over sales of $409.05 million the same period last year.

Earnings

Earnings Misses

TSX:CF

Canaccord Genuity Group Q4 Adj. EPS $0.12 Misses $0.17 Estimate, Sales $461.23M Miss $466.95M Estimate

<a href="https://www.reuters.com/sustainability/boards-policy-regulation/doordash-grubhub-uber-eats-settle-with-new-york-city-over-fee-caps-2025-06-04/">https://www.reuters.com/sustainability/boards-policy-regulation/doordash-grubhub-uber-eats-settle-with-new-york-city-over-fee-caps-2025-06-04/</a>

General

DASH

UBER

'DoorDash, Grubhub, Uber Eats settle with New York City over fee caps'- Reuters

In the current session, the stock is trading at $687.33, after a 3.07% increase. Over the past month, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) stock increased by 15.27%, and in the past year, by 39.33%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749074431_0.png" alt="Past Year Chart" />

<h3>Comparing Meta Platforms P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Meta Platforms has a lower P/E than the aggregate P/E of 34.6 of the Interactive Media &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749074431_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Meta Platforms Inc's Price Over Earnings

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 5 years by 7.9% on an annualized basis producing an average annual return of 21.09%. Currently, Caterpillar has a market capitalization of $164.11 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 5 years ago, it would be worth $253.65 today based on a price of $348.93 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749074414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Caterpillar 5 Years Ago Would Be Worth Today

A movie about the <a href="https://www.benzinga.com/news/23/12/36171063/what-really-happened-with-sam-altman-getting-fired-as-openai-ceo-new-details-emerge">firing and rehiring</a> of OpenAI co-founder and CEO Sam Altman is in the works.
Here are the early details.
What Happened: Best known as the parent company of ChatGPT, OpenAI has been one of the most talked about AI companies in recent years. The company has also faced a handful of controversies, including <a href="https://www.benzinga.com/25/02/43609104/elon-musk-co-founded-openai-now-hes-bidding-974b-to-take-back-the-company">a legal battle</a> with Elon Musk.
One of the company's controversies is being turned into a movie tentatively titled "Artificial."
The film will center on the firing and rehiring of Altman that happened back in 2023, as <a href="https://www.hollywoodreporter.com/movies/movie-news/luca-guadagnino-to-direct-openai-movie-1236236357/">reported </a>by The Hollywood Reporter.
The film is being produced by Amazon MGM Studios, a unit of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). The report did not say if the film would hit movie theaters or be streamed on Prime Video.
Luca Guadagnino, who has been behind films like "Challengers," "Call Me By Your Name" and "Suspiria" is set to direct the true-life film.
Among the actors attached to the film are Andrew Garfield, Monica Barbaro, and Yura Borisov. Garfield, who has played Spider-Man in films, is said to be the frontrunner to portray Altman in the film. Barbaro is in talks to play chief technology officer Mira Murati, and Borisov would play OpenAI co-founder Ilya Sutskever, according to the report.
Read Also:<a href="https://www.benzinga.com/news/23/03/31266515/5-things-you-might-not-know-about-openai-founder-sam-altman-doomsday-prepper-donald-trump-critic-and"> 5 Things You Might Not Know About OpenAI Founder Sam Altman: Doomsday Prepper, Donald Trump Critic And More</a>
What's Next: While no casting decisions have been made, the report said things are moving fast and the movie could go into production this summer.
Altman is best known as the co-founder and CEO of OpenAI. In 2023, the company&#8217;s Board of Directors fired him, with reports that Sutskever led the decision.
The movie would likely center on the reasons why Altman was let go and why he was quickly hired back to lead the company.
Sutskever<a href="https://www.benzinga.com/news/24/05/38834519/openai-chief-scientist-ilya-sutskever-steps-down-ceo-sam-altman-calls-him-a-guiding-light-of-ai-fiel"> stepped down</a> from OpenAI in 2024 and went on to found another AI company called Safe Superintelligence. That company was valued at a reported $30 billion <a href="https://www.benzinga.com/tech/25/02/43772135/ex-openai-chief-scientist-ilya-sutskevers-ai-startup-valued-at-30-billion-in-latest-funding-round-report">earlier this year.</a>
OpenAI <a href="https://www.benzinga.com/25/04/44580172/openai-finalizes-historic-40-billion-funding-round-valuing-company-at-300-billion-with-backing-from-softbank-and-microsoft">is valued at </a>$300 billion with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) one of the largest investors in the AI company.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45739990/microsoft-brings-openais-sora-to-the-masses-with-free-ai-video-generator-in-bing-app-after-googles-v">Microsoft Brings OpenAI&#8217;s Sora To The Masses With Free AI Video Generator In Bing App After Google&#8217;s Veo 3 Wowed The Internet—Here&#8217;s What You Can (And Can&#8217;t) Do</a></li>
</ul>
Photo: jamesonwu1972/Shutterstock

Entertainment

Tech

AMZN

MSFT

Sam Altman's 2023 OpenAI Ouster Becoming A Movie: Could Former Spider-Man Play Him?

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 5 years by 4.46% on an annualized basis producing an average annual return of 17.65%. Currently, Halozyme Therapeutics has a market capitalization of $6.59 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 5 years ago, it would be worth $2,250.31 today based on a price of $53.51 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749073516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HALO

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years

<a href="https://www.bloomberg.com/news/articles/2025-06-04/walmart-pledges-transparency-on-prices-after-drawing-trump-s-ire?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-04/walmart-pledges-transparency-on-prices-after-drawing-trump-s-ire?embedded-checkout=true</a>

'Walmart Pledges Transparency on Prices After Drawing Trump's Ire'- Bloomberg

Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares closed Wednesday up 0.5% at $141.92. The company announced that its Blackwell architecture delivered breakthrough performance in its latest training results.
What To Know: The volatility in Nvidia shares on Wednesday came as the company said in a blog post that its AI platform delivered the highest performance at scale on all benchmarks and powered every result submitted on the benchmark's toughest large language model-focused test. 
Blackwell delivered more than 2x greater performance compared with the company&#8217;s previous-generation architecture. The company said the results underscore the platform&#8217;s exceptional performance and versatility across a wide array of AI workloads. Nvidia presented at the BofA Securities 2025 Global Technology Conference on Wednesday. 
Nvidia made headlines earlier this week by <a href="https://www.benzinga.com/markets/tech/25/06/45763363/nvidia-overtakes-microsoft-as-the-worlds-most-valuable-company-with-3-4-trillion-market-cap-as-morgan-stanley-reaffirms-top-pick-status">overtaking Microsoft </a>to become the world's most valuable company, now valued at approximately $3.44 trillion. The jump in shares follows strong first-quarter earnings in which the company reported $44.1 billion in revenue, representing a 69% year-over-year increase, ahead of Wall Street expectations. 
Analysts at Morgan Stanley maintained Nvidia as a top pick, citing growing demand for its AI chips across data centers and gaming. Several other analysts raised price targets over the past week, ranging from $135 to $210.
Wedbush&#8217;s Dan Ives said earlier this week that Nvidia could <a href="https://www.benzinga.com/markets/equities/25/06/45767936/tech-bull-says-nvda-can-be-a-250-stock-if-trump-takes-a-step-back-from-tariffs">climb to $250</a> per share over the coming years if the Trump administration pulls back on tariffs. He also indicated that new all-time highs are on the horizon for tech stocks. The broader semiconductor sector got a boost on Wednesday after GlobalFoundries announced plans to commit $16 billion towards U.S. chip expansion. The move is part of an industry-wide reshoring trend driven by AI demand and ongoing trade tensions. The expansion includes new investments in silicon photonics, GaN power technologies and advanced packaging, all critical for energy-efficient AI chips.
Nvidia continues to benefit from strong institutional and investor confidence tied to the long-term demand for AI infrastructure.
NVDA Price Action: Nvidia shares are up about 21% over the past month, and the stock has climbed more than 5% over the past week, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45777558/stocks-stall-on-weak-economic-data-treasuries-eyes-best-rally-in-7-months-whats-driving-markets-wednesday">Stocks Stall On Weak Economic Data, Treasuries Eyes Best Rally In 7 Months: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Image via Shutterstock.

Movers

NVDA

What's Going On With Nvidia Stock?

Gran Tierra Energy To Sell Gran Tierra North Sea Limited To NEO Energy For $7.5M

Transcontinental (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TCL#TSX">TCL</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.54 by 7.41 percent. This is a 11.54 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $684.10 million which beat the analyst consensus estimate of $662.74 million by 3.22 percent. This is a 0.13 percent increase over sales of $683.20 million the same period last year.

Earnings Beats

TSX:TCL

TSX:TCL.A

Transcontinental Q2 Adj. EPS $0.58 Beats $0.54 Estimate, Sales $684.10M Beat $662.74M Estimate

FOUR

Shift4 Payments Restructuring Transactions Agreement Terminated Due To Unmet Conditions

Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) has outperformed the market over the past 15 years by 15.43% on an annualized basis producing an average annual return of 27.41%. Currently, Monolithic Power Systems has a market capitalization of $33.89 billion. 
Buying $100 In MPWR: If an investor had bought $100 of MPWR stock 15 years ago, it would be worth $3,870.47 today based on a price of $694.75 for MPWR at the time of writing.
<h3>Monolithic Power Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749072622_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPWR

$100 Invested In Monolithic Power Systems 15 Years Ago Would Be Worth This Much Today

Management

Shift4 Payments Jared Isaacman Resigns As Shift4 Payments CEO Effective June 5, 2025; Taylor Lauber Appointed As New Shift4 Payments CEO; Jared Isaacman Appointed Executive Chairman Of Shift4 Payments

<a href="https://www.reuters.com/sustainability/boards-policy-regulation/apple-loses-bid-pause-app-store-reform-order-epic-games-case-2025-06-04/">https://www.reuters.com/sustainability/boards-policy-regulation/apple-loses-bid-pause-app-store-reform-order-epic-games-case-2025-06-04/</a>

AAPL

'Apple loses bid to pause app store reform order in Epic Games case'- Reuters

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 10 years by 5.64% on an annualized basis producing an average annual return of 16.72%. Currently, Marvell Tech has a market capitalization of $56.99 billion. 
Buying $100 In MRVL: If an investor had bought $100 of MRVL stock 10 years ago, it would be worth $477.32 today based on a price of $66.10 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749071712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

$100 Invested In Marvell Tech 10 Years Ago Would Be Worth This Much Today

Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/SIG/earnings">raised its FY26 guidance on Tuesday.</a>
The company posted revenue of $1.54 billion, a 2% increase from the prior year, surpassing analysts&#8217; consensus estimate of $1.49 billion. Adjusted EPS of $1.18 beat the consensus estimate of $1.07.
"We delivered positive same-store sales growth each month of the quarter, and into May, by bolstering our offerings at key price points and continuing the evolution of our assortment. Our three largest brands – Kay, Zales, and Jared – all saw sequential comp sales improvement from the fourth quarter on higher margins, highlighting the impact of our outsized focus on our larger brands," stated J.K. Symancyk, Chief Executive Officer.
Signet raised its 2026 revenue guidance to a range of $6.57 billion to $6.80 billion, up from $6.53 billion to $6.80 billion, compared with the consensus estimate of $6.69 billion.
The company increased its adjusted EPS forecast to $7.70 to $9.38, up from $7.31 to $9.10, versus the consensus of $8.45. It expects adjusted EBITDA between $615 million and $695 million, slightly higher than the prior range of $605 million to $695 million.
For the second quarter, Signet projects revenue of $1.47 billion to $1.51 billion, above the $1.34 billion estimate, and adjusted EBITDA of $53 million to $73 million.
Signet Jewelers shares fell 1.1% to close at $74.40 on Wednesday.
These analysts made changes to their price targets on Signet following earnings announcement.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Dana Telsey maintained Signet Jewelers with a Market Perform and raised the price target from $62 to $80.</li>
<li>B of A Securities analyst Lorraine Hutchinson maintained the stock with a Neutral and raised the price target from $65 to $78.</li>
<li>Wells Fargo analyst Ike Boruchow maintained Signet Jewelers with an Equal-Weight and raised the price target from $70 to $75.</li>
<li>UBS analyst Mauricio Serna maintained the stock with a Buy and raised the price target from $84 to $95.</li>
<li>Citigroup analyst Paul Lejuez maintained Signet Jewelers with a Buy and raised the price target from $85 to $100.</li>
</ul>
Considering buying SIG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SIG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-1024x548.png" alt="" class="wp-image-938834" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55.png 1052w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>

Price Target

These Analysts Increase Their Forecasts On Signet Jewelers After Better-Than-Expected Q1 Earnings

EBTC

INDB

Independent Bank And Enterprise Bancorp Receive All Required Regulatory Approvals Relating To The Proposed Transaction; The Proposed Transaction Is Expected To Be Completed On July 1, 2025

DVAX

Dynavax Technologies Comments On A Report Published By Glass, Lewis & Co; Says Is Already Delivering Significant Long-Term Stockholder Value Through Execution Of Current Strategy Overseen By Board; Deep Track's Inferior Short-Term Plan And Nominees Are Not In The Best Interests Of All Stockholders

Press Releases

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Health Care

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

The Future of Stem Cell Investing: Spotlight on Smaller Innovators

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

Comments

CRISPR Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL